As of 2026 you can take a GLP-1 as a daily pill or a weekly injection. Pills are newer, cheaper and needle-free, but the strongest results still come from an injection: tirzepatide averaged 20.2% body-weight loss in head-to-head trial data, versus 16.6% for the oral semaglutide pill and 12.4% for orforglipron. The right choice depends on your health history, not the headline.
For most of the last decade, “weight-loss medication” meant a weekly injection. That changed twice in the space of four months. In December 2025 the FDA approved a 25 mg oral semaglutide tablet, the first GLP-1 pill indicated for chronic weight management. In spring 2026 it approved orforglipron, sold as Foundayo, the first non-peptide oral GLP-1, which does not carry the fasting and water restrictions that oral peptides require.
The result is that patients walking into our Hinsdale and Arlington Heights clinics now ask a question that did not exist eighteen months ago: should I be on a pill instead of a shot?
This article lays out what the trial data actually shows, what each option costs in 2026, and how our physicians decide between them. It is general information, not a prescription — the honest answer for any individual depends on labs, cardiac history and medication list, which is why we run those before we prescribe anything.
What actually changed in 2026
Two approvals reshaped the category, and a third fact explains why everyone is talking about it.
Oral semaglutide 25 mg (Wegovy tablet) was approved on 22 December 2025 for chronic weight management and cardiovascular risk reduction in adults with obesity, or overweight plus at least one weight-related condition. It is the same molecule as the Wegovy injection, reformulated for daily oral dosing (manufacturer announcement).
Orforglipron (Foundayo) followed in spring 2026. It matters for a structural reason: it is a small-molecule, non-peptide GLP-1 receptor agonist. Peptides are fragile in the stomach, which is why oral semaglutide has to be taken on an empty stomach with a specific small volume of water. Orforglipron does not — it can be taken with or without food and water. It was cleared in roughly 50 days under the FDA’s National Priority Voucher pilot, the fastest new molecular entity approval since 2002.
And the context: about 11% of American adults now report currently taking a GLP-1 medication for weight loss, up from 3% in 2024, according to Gallup polling. This is no longer a niche therapy.
The efficacy question, answered with numbers
Convenience is easy to market. Effectiveness is what patients actually care about. Here is what the trials report.
Average body-weight reduction by medication
Sources: SURMOUNT-5 head-to-head (tirzepatide vs. semaglutide injections); OASIS 4 phase 3 (oral semaglutide, 64 weeks, with reduced-calorie diet and exercise); orforglipron 72-week phase 3. Trial populations and durations differ, so these are not perfectly like-for-like comparisons.
The three options, side by side
| Tirzepatide (Zepbound) | Oral semaglutide (Wegovy pill) | Orforglipron (Foundayo) | |
|---|---|---|---|
| Form | Weekly injection | Daily tablet | Daily tablet |
| Mechanism | GIP + GLP-1 (dual) | GLP-1 (peptide) | GLP-1 (non-peptide) |
| Average weight loss | 20.2% | 16.6% | 12.4% |
| Food/water rules | None | Empty stomach, limited water | None |
| Approx. cash price (2026) | ~$550/mo | ~$299/mo | $149–$299/mo |
| Approved for weight loss | Yes | Dec 2025 | Spring 2026 |
Prices above are 2026 cash/list figures before insurance and change frequently; treat them as a starting point, not a quote.
A closer look at the Wegovy pill
The approval rested on OASIS 4, a phase 3 trial that followed 307 adults without diabetes for 64 weeks. Participants took a daily tablet titrated over a 12-week escalation phase (available strengths run 1.5 mg, 4 mg, 9 mg and 25 mg) alongside a reduced-calorie diet and increased physical activity.
Average weight loss was 16.6% with the lifestyle programme, roughly 14% attributable to the drug itself, against about 3% on placebo. One in three participants lost 20% or more of their body weight. Notably, serious adverse events were less frequent on the drug than on placebo (3.9% versus 8.8%) — a reassuring signal, though a 307-person trial is not the same evidence base as years of post-market surveillance.
The practical catch is the dosing ritual. Oral peptides degrade in the stomach, so the tablet must be taken on an empty stomach with a small, specified amount of water, and you wait before eating or drinking anything else. Patients who are chaotic in the mornings tend to struggle with this, and a GLP-1 you take inconsistently is a GLP-1 that underperforms.
A closer look at orforglipron
Orforglipron trades peak efficacy for freedom. Because it is not a peptide, there is no empty-stomach rule and no water restriction — you take it like any other daily tablet.
In its 72-week phase 3 programme, participants on the highest dose who stayed on treatment lost an average of 27.3 lb (12.4%), versus 2.2 lb (0.9%) on placebo. Across all treated participants regardless of adherence, the average was 25 lb (11.1%) versus 5.3 lb (2.1%). That gap between “completers” and “everyone” is worth noticing — it is a reminder that these medications only work while you take them.
What each option costs
Approximate monthly cash cost, 2026 (before insurance)
List/cash prices as reported in 2026, before insurance or manufacturer savings programmes. Commercial insurance can bring costs to a fraction of these figures; coverage for weight-loss indications varies widely by plan.
Cost is where the pills genuinely disrupt things. Orforglipron at the low end of its range is roughly a quarter of brand tirzepatide. For a patient paying cash — which, in Illinois, is a great many patients, because weight-loss indications are inconsistently covered — that difference decides what is realistic to sustain for a year.
Side effects: what to actually expect
Every medication in this class shares a broadly similar side-effect profile, because they all slow gastric emptying and act on appetite signalling. The most common effects are gastrointestinal: nausea, constipation, diarrhoea, reflux and a feeling of fullness that arrives faster than you are used to. For most patients these are worst during dose escalation and settle as the body adapts.
Three things reduce them substantially, and none of them are complicated. Titrate slowly rather than rushing to the top dose. Eat smaller portions, more slowly, and stop at the first sense of fullness rather than the plate being empty. Keep fluid and fibre up, because constipation is the effect patients most often underestimate.
What is worth understanding is that side effects are not simply a nuisance to be endured — they are information. Persistent vomiting, severe abdominal pain radiating to the back, or symptoms that arrive suddenly after months of stability are reasons to contact your clinician the same day, not to push through. Rarer but serious concerns in this class include pancreatitis and gallbladder disease, and there is a boxed warning relating to thyroid C-cell tumours observed in rodents, which is why a personal or family history of medullary thyroid carcinoma or MEN2 rules these medications out.
This is the practical argument for supervised care rather than a mail-order prescription. Somebody has to be available to tell you which symptoms are ordinary adaptation and which are not, and to adjust the dose rather than leaving you to abandon treatment because week three was unpleasant.
Who should not take a GLP-1
These medications are genuinely transformative for the right patient and inappropriate for others. Absolute and relative contraindications include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, a history of pancreatitis, active gallbladder disease, severe gastrointestinal motility disorders such as gastroparesis, pregnancy or active attempts to conceive, and a history of an eating disorder, where appetite suppression can be actively harmful.
There are also interactions that matter. Because these drugs slow gastric emptying, they can alter the absorption of oral medications taken alongside them. Patients on insulin or sulfonylureas need those doses reviewed to avoid hypoglycaemia. None of this is exotic — it is ordinary prescribing diligence, and it requires somebody to have your full medication list in front of them.
This is also where our prescription appetite suppressant options and medically supervised meal replacement programme come in. A GLP-1 is not the only route to meaningful weight loss, and for patients who cannot take one, or cannot afford one long term, they are not the end of the conversation.
So which one is right?
There is no universal answer, and any clinic that gives you one without looking at your history is guessing. In our practice the decision usually turns on five things.
1. Your cardiac and medical history
This is first for a reason. GLP-1 medications affect heart rate and gastrointestinal motility, and some patients have contraindications they do not know about. We run an in-office EKG and baseline bloodwork before prescribing, because the safest option on paper is not always the safest option for you.
2. Whether you will actually take it
A weekly injection is one decision per week. A tablet is seven, and in the case of oral semaglutide, seven decisions with a fasting rule attached. Patients who travel, work nights or have unpredictable mornings often do better on the weekly shot despite the needle.
3. Your target
If you and your physician are aiming at a large reduction — typically because of obesity-related conditions such as sleep apnea, fatty liver or type 2 diabetes risk — the dual-agonist injection currently has the strongest data.
4. Needle aversion
It is not a trivial factor. A meaningful number of people will not start an injectable at all. A pill they will take beats an injection they will not.
5. What you can sustain financially
Stopping a GLP-1 generally means regaining weight. Choosing a medication you can afford for twelve months matters more than choosing the one with the best trial number for three.
What the first 90 days actually look like
Patients often expect the graph to go straight down from week one. It rarely does, and knowing the real shape of it prevents a lot of unnecessary discouragement.
A typical first 90 days on a GLP-1
Illustrative pattern based on standard titration schedules and typical clinical course. Individual response varies considerably.
The first month is mostly about tolerance, not weight. You are on a starting dose chosen to minimise side effects, and what most people notice first is not the scale but the quiet: the constant background negotiation with food gets quieter. That is the drug working, even when the number has barely moved.
Weeks five through eight are usually where consistent loss begins, as the dose steps up. This is also the window where what you eat starts to matter disproportionately. Appetite suppression makes it easy to under-eat protein, and under-eating protein while losing weight rapidly is how people lose muscle alongside fat. We push protein targets and resistance training hard here, for that reason.
By the third month the goal shifts from escalation to optimisation — finding the lowest dose that holds your appetite where you need it, rather than automatically climbing to the maximum. Many patients hit their first plateau somewhere around here. It is expected, it is not failure, and it is usually solvable.
How we approach this at ThinfastMD
We have practised medically supervised weight management in Illinois since 1984, which means we have watched several generations of weight-loss drugs arrive with enormous claims. Our approach has not changed with the pills: assess first, prescribe second.
A new patient visit includes a consultation, a physical exam and vitals, an in-office EKG and baseline lab work. That work-up tells us whether a GLP-1 is appropriate at all, whether an appetite suppressant is a better fit, whether a meal-replacement programme would serve you better, and whether something treatable — a thyroid problem, insulin resistance — is contributing to the weight you have been fighting.
Where we see patients
ThinfastMD operates four Illinois clinics, and patients travel to us from across Chicagoland and the Rockford area:
- Hinsdale — serving Oak Brook, Clarendon Hills, Burr Ridge, Western Springs, Downers Grove, Westmont and Naperville
- Brookfield — serving Riverside, Berwyn, La Grange and Oak Park
- Arlington Heights — serving Palatine, Schaumburg, Mount Prospect, Buffalo Grove and Des Plaines
- Rockford — serving Loves Park, Machesney Park, Cherry Valley and Roscoe
See all four clinics, hours and directions
Not sure which option fits you?
Start with a real medical evaluation, not an online questionnaire.
Frequently asked questions
Is the weight-loss pill as good as the injection?
Not universally. The oral semaglutide tablet averaged 16.6% body-weight loss in the OASIS 4 trial, which is strong, while orforglipron averaged 12.4%. The tirzepatide injection still leads at 20.2% in head-to-head data. The best option depends on your health history, your adherence pattern and your budget rather than on the form of the medication.
Do I still need bloodwork if I am taking a pill instead of an injection?
Yes. The route of administration does not change the medication’s effects on your body. Baseline labs and an EKG tell your physician whether a GLP-1 is safe for you and give a reference point to monitor against. We include both in our new patient visit.
What happens if I stop taking it?
Most people regain a substantial portion of the weight. These medications treat obesity as a chronic condition, similar to how blood-pressure medication treats hypertension. That is why we plan for maintenance from the start rather than treating it as a short course.
Can I switch from an injection to a pill?
Often yes, but it is not a simple swap. Dosing does not translate one-to-one between molecules, and switching usually means a new titration schedule. It should be done with your prescriber, not by adjusting on your own.
Is compounded semaglutide still an option in 2026?
The rules have tightened considerably. The FDA declared the semaglutide shortage resolved in February 2025, and in April 2026 proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List. A narrow patient-specific 503A pathway remains, and clinicians at Stanford Medicine have flagged safety concerns with compounded versions. If you are considering compounded medication, ask exactly which pathway your pharmacy is using.
Does insurance cover any of this in Illinois?
Coverage for weight-loss indications is inconsistent and plan-specific. Some commercial plans cover GLP-1s with prior authorisation, many exclude weight-loss indications entirely, and Medicare coverage is limited. Our team will tell you plainly what your plan does and does not cover before you commit to a programme.
Medical disclaimer. This article is general health information and is not medical advice, diagnosis or treatment. Weight-loss medications are not appropriate for everyone and carry risks, including gastrointestinal effects and contraindications in certain cardiac, thyroid and pancreatic conditions. Individual results vary. Trial figures cited reflect specific study populations and protocols and may not predict your outcome. Pricing reflects 2026 reporting and changes frequently. Always consult a qualified clinician before starting, stopping or changing any medication.
